August 5, 2021
RFA-HS-22-001 - Reducing Racial and Ethnic Healthcare Disparities in Chronic Conditions by Dissemination and Implementation of Patient Centered Outcomes Research (PCOR) Evidence (R18).
RFA-RM-22-001 - Limited Competition: Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Optional)
NOT-OD-22-049 - Notice of Change to NIHs Policy on Special Council Review of Research Applications
PAR-22-044 - NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)
PAR-22-041 - NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)
PAR-22-042 - NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)
PAR-22-060 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
NOT-OD-22-018 - Reminder: FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2022 - New Grant Application Instructions Now Available.
NOT-OD-21-073 - Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021
NOT-OD-21-109 - Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel
NOT-OD-21-110 - Implementation of Changes to the Biographical Sketch and Other Support Format Page
NOT-OD-21-122 - Announcing New Inbox for Inquiries Related to Changes to Biographical Sketch and Other Support Format Page
NOT-OD-21-170 - Updates: Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements
NATIONAL INSTITUTES OF HEALTH (NIH)
U.S. Food and Drug Administration (FDA)
Agency for Healthcare Research and Quality (AHRQ)
This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after January 25, 2022.
The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.
Key changes:
See High-level Summary of Form Changes in FORMS-G Application Packages for a full list of form changes. Participating agencies will notify the community if it is determined additional changes are needed. These changes will be implemented with application form packages identified with a Competition ID of "FORMS-G" and associated application guide instructions. Additional guidance and confirmation ofimplementation plans will be provided in Fall 2021.
Effective Date
Applicants must use FORMS-G application packages for due dates on or after January 25, 2022 and must use FORMS-F application packages for due dates on or before January 24, 2022. Applications submitted using the wrong forms for their intended due date may be withdrawn and removed from funding consideration.
Availability of FORMS-G Application Guides
Application guides for FORMS-G application packages will be posted to the How to Apply - Application Guide page no later than October 25, 2021.
Availability of FORMS-G Application Packages
FORMS-G application packages will be posted as follows
For a transition period, both FORMS-F and FORMS-G application packages will be active simultaneously. Applicants must choose the appropriate application package for their due date when presented with both FORMS-F and FORMS-G application packages on the same FOA (see table below).
If your intended due date is... | You must use... |
---|---|
On or before January 24, 2022, including:
|
FORMS-F application package |
On or after January 25, 2022, including:
|
FORMS-G application package |
Applications submitted using the incorrect application package for their due date may be withdrawn and removed from funding consideration.
Resources:
Please direct all NIH inquiries to:
NIH Office of Policy for Extramural Research Administration (OPERA)
Systems Policy Branch
Email: [email protected]
Please direct all AHRQ inquiries to:
Division for Policy, Coordination and Analysis
Office of Extramural Research, Education, and Priority Populations
Agency for Healthcare Research and Quality, HHS
Email: [email protected]
Please direct all FDA inquiries to:
Food and Drug Administration (FDA)
Office of Acquisitions and Grants Services (OAGS)
Grants Management Branch
Email: [email protected]